Mirion Technologies 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Mirion Technologies reported second quarter 2026 total revenue of $267 million, a 20% increase year over year, with organic revenue growth of 1%.
- Second quarter adjusted EBITDA was $65 million, up 27.5% from last year, with margins expanding 150 basis points driven by favorable product mix and pricing.
- Orders grew 10% year over year, led by a 50% increase in nuclear power orders excluding M&A, including $49 million in small modular reactor (SMR) orders.
- Backlog at the end of Q2 totaled over $1.1 billion, nearly 40% higher than a year ago, with legacy backlog up 17% and legacy installed base backlog up nearly 40%.
- The company used $25 million of its $100 million share repurchase program in Q2, buying back approximately 1.4 million shares.
- Adjusted free cash flow was $49 million in Q2, bringing first half 2026 adjusted free cash flow to $60 million, the best first half since going public.
- The medical segment revenue declined 1% organically due to delayed hardware demand in nuclear medicine and dosimetry, but software business showed strong double-digit order growth.
- The company experienced an $18 million cancellation of a Chinese new build order originally booked in 2019 due to geopolitical tensions, with no impact on 2026 guidance and immaterial impact on long-range guidance.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings. Welcome to the Mirion Technologies second quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Eric Linn, Treasurer and Head of Investor Relations. Thank you, Eric. You may begin.
Hey. Thank you, Liz, and good morning, everyone. Welcome to Mirion's second quarter 2026 earnings conference call. Joining me this morning are Mirion's Founder, Chairman, and CEO, Tom Logan, and Mirion's CFO and Medical Group President, Brian Schopfer. Before we begin today's prepared remarks, allow me to remind you that comments made during this call will include forward-looking statements. Actual results may differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our annual reports on Form 10-K, quarterly reports on Form 10-Q, and in Mirion's other SEC filings under the caption Risk Factors. Quarterly references within today's discussion are related to the second quarter ended June 30th, 2026, unless otherwise noted. The comments made during this call will also include certain financial measures that were not prepared in accordance with generally accepted accounting principles.
Reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the appendix of the presentation accompanying today's call. All earnings materials can be found in the investor relations section of our website at www.mirion.com. With that, let me now turn the call over to Tom, who will begin on panel three.
Eric, thank you. Good day to everyone joining on the call today. Yesterday, after market close, we issued our second quarter results. Once again, we demonstrated growing orders and backlog, including key large opportunity order wins. This double-digit order growth is fueling continued backlog expansion as the nuclear power momentum continues to take hold. We also demonstrated expanding Adjusted EBITDA margins from both operating segments and across the total enterprise. Better mix and pricing helped to more than offset the dilutive impacts from M&A and broader inflation headwinds. All of this is setting the stage for a strong second half 2026 acceleration. We're maintaining our 2026 full-year guidance, which implies a meaningful step-up in financial performance for the remainder of the year. Brian will walk you through the details, including expectations for the third quarter and the second half.
We continue to believe that the momentum in nuclear power is building. Nowhere is this more evident than right here in North America. As I've said on prior calls, the nuclear super trend continues to broaden, and this quarter's headlines, highlighted on panel four, make that abundantly clear. Here in the U.S., regulatory and policy improvements are supporting momentum within nuclear power. The NRC has proposed updates designed to streamline the licensing process, eliminating unnecessary burdens and increasing regulatory clarity, while importantly maintaining safety standards. Pair that with the Department of Energy's $17.5 billion loan program to support new reactor builds, and you can see both the financing and regulatory gateways beginning to open up simultaneously. We're also encouraged by execution, not just policy. The DOE's reactor pilot program achieved criticality across four advanced reactor designs, outperforming its own target of three by the July 4th deadline.
That's a tangible example that small modular reactor designs are progressing. Importantly, Mirion, Paragon, and Certrec were squarely in the mix on each of these advanced reactor designs. On the demand side, new power deals continue to materialize. Constellation and Walmart announced a new nuclear power agreement, Walmart's first, and amongst the first between a large retailer and a nuclear facility in this country. Additionally, New York State and Canada are advancing their nuclear plans to add additional capacity. Moreover, just last week, the U.S. announced a deal with Saudi Arabia to supply new reactors and nuclear technology, creating another avenue of incremental nuclear demand. Each of these examples in just the past few months showcase the well-timed acquisitions of Paragon and Certrec to leverage their market-leading positions within North America.
Looking beyond North America on panel five, fresh data from the World Nuclear Association reinforces what we're already seeing take hold, a generational build-out of global nuclear capacity. Today, the world operates at approximately 400 gigawatts of nuclear capacity. Latest projections forecast a tripling of total global capacity by 2050 to nearly 1.5 terawatts. This is a 45% increase compared to projections a decade ago. Even excluding growth from China and Russia, global capacity still grows at a staggering 2x. Each projection on this panel points in the same direction, increased demand for Mirion solutions and an expanding installed base that provides recurring demand for decades to come. Recall, approximately 80% of our nuclear power-based revenue comes from today's installed base and is the source of considerable recurring and repeat revenue. Panel six focuses on the near to medium-term. Reactors operating today are providing foundational demand growth.
At a high level, we're seeing three waves of installed base nuclear customer demand. The first wave is catch-up capital spending. Decades of capital rationing across the operating fleet left operators with a backlog of deferred maintenance and required replacement parts. Add in the funnel of plant restarts we've talked about, and you get an outsized near-term call on commercial-grade dedication, reverse engineering, and spare parts out of our Paragon platform. The second wave is life extensions and extended power upgrades. Once an operator makes the decision to life extend, they have greater visibility to operate for another 10 to 20 years. This triggers upgrade decisions to instrumentation and controls and broader plant ecosystems. The third wave is emerging, but it's coming. Digital transformation. The nuclear workforce is aging out, and with it goes decades of tribal knowledge.
Replacing these workers are digital natives increasingly looking toward digital platforms to capture and scale that expertise. Additionally, digital platforms are providing the firepower to optimize outages and assist operators in improving thermal efficiency. We're already seeing these factors drive order growth, as illustrated on panel seven. Second quarter 2026 backlog totals over $1.1 billion. This is nearly 40% higher versus a year ago. Legacy backlog, excluding backlog additions from the Paragon and Certrec deals, has grown by 17%. Let's drill into this legacy backlog number a bit to illustrate my broader point about growing nuclear power demand. This subset of the backlog has seen incredible growth, up 31% versus 17% for total legacy Mirion. If you isolate the legacy Mirion installed base, it's even more impressive, up nearly 40% versus Q2 2025. Panel eight addresses investor questions on the second half revenue visibility.
We continue to have good line of sight to our full-year revenue expectations. Between first half actual results and backlog expected to convert to revenue in the second half, approximately 81% of our expected full-year revenue is accounted for. Importantly, this 81% shows comparable revenue coverage to prior years. This gives us the confidence to maintain full-year revenue expectations. Additionally, Paragon's Peaks business adds a new revenue stream for us that does not appear in backlog. Instead, this revenue is booked in-quarter. Before I turn it over to Brian to detail the quarter, allow me to spend a minute on AI, shown on panel nine. This is where an increasing amount of my time is spent today, thinking strategically and guiding our business to harness the incredible potential from artificial intelligence.
We're investing to create early adopter advantage by embedding AI into how we develop products, how we serve customers, and how we run our operations. We've organized our AI strategy across three distinct pillars with dedicated resources committed to accelerating adoption and deployment across the company. The first pillar is accelerating product development. AI is fundamentally changing our software development cycles and compressing time to market. Specifically, we're improving data analytics, accelerating real-time feedback loops, and improving testing and compliance workflows that would have taken our engineering teams months to execute manually. The ability to move faster while maintaining, and in fact, improving the rigor of our compliance processes is a genuine game changer. The second pillar is organization-wide efficiencies. AI is becoming an important tool in this effort, from automating back-office processes like document review to test plan development.
We're still in the early innings here, but the trajectory is encouraging, and the internal adoption is gaining traction. The third pillar, the one I'm most excited about, is AI-powered solutions. We're developing new AI-centric innovations across both segments. Importantly, we are increasingly focused on connecting our hardware devices. Think instruments that sit in nuclear power plants and cancer treatment centers around the world to software and data platforms that drive measurable productivity improvements for our customers. In fact, last week at the AAPM annual meeting in Vancouver, we highlighted our new Plan AI Dosimetry platform, which enables dosimetrists to deliver higher-quality patient-specific plans faster. In our RTQA business, we also highlighted our new Daily QA 4 Pro, which consolidates dosimetry and imaging checks into a single indexed imageable solution, reducing room entries, minimizing setup time, and standardizing execution across users.
Importantly, it is integrated into our existing SunCHECK platform so physics teams can spend less time on logistics and more time on patient care. Let me turn it over now to Brian to walk through the financials.
Brian? Thank you, Tom. Good morning, everyone.
I'll continue the prepared remarks on slide 10, outlining our financial performance. Second quarter total revenue was $267 million, an increase of 20% versus last year's second quarter. Organic revenue growth was 1%, in line with our expectations and aligned with what we communicated in April. Second quarter Adjusted EBITDA was $65 million or 27.5% higher than last year. Margins expanded 150 basis points in the quarter, driven by favorable product mix and price across both segments. Excluding the impacts of M&A and a one-time tariff refund, margins would have expanded over 200 basis points. We've received approximately $1 million in tariff refunds to date. Based on how the stock is traded, we used approximately $25 million of our $100 million share repurchase program in the second quarter to opportunistically buy back approximately 1.4 million shares.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
